Novo Nordisk A/S (NYSE:NVO) Short Interest Update

Key Points

• Short interest fell 19.3% to 19,927,815 shares as of March 31, equal to 0.4% of the stock and a short‑interest ratio of about 1.1 days based on average daily volume.
• Novo announced a strategic partnership with OpenAI to accelerate drug discovery and manufacturing, and the UK approved a single‑dose 7.2 mg Wegovy pen — near‑term R&D and commercial catalysts for its obesity/diabetes franchise.
• Competitive dynamics are mixed: a preprint suggests semaglutide may better preserve lean mass versus Eli Lilly’s tirzepatide and Lilly faces an FDA data request, but low‑cost generic semaglutide from India’s Hetero could pressure pricing and share long term.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) saw a large drop in short interest in March. As of March 31st, there was short interest totaling 19,927,815 shares, a drop of 19.3% from the March 15th total of 24,696,357 shares. Currently, 0.4% of the company's stock are short sold. Based on an average daily volume of 18,061,163 shares, the short-interest ratio is presently 1.1 days.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Opened a strategic partnership with OpenAI to deploy advanced AI across drug discovery, manufacturing and commercial operations — aimed at accelerating R&D, improving efficiency and helping Novo defend its lead in obesity/diabetes therapeutics. NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up
• Positive Sentiment: UK regulator approved a single‑dose 7.2 mg Wegovy pen for adults, expanding Wegovy’s dosing options and market availability in a major market. This is a near-term commercial win for Novo’s obesity franchise. UK approves Novo Nordisk single-dose 7.2mg Wegovy pen for adults
• Positive Sentiment: New study (pre-peer-review) suggests semaglutide may preserve lean body mass better than Eli Lilly’s tirzepatide — a data point investors could reward as it supports semaglutide’s clinical profile vs. a key competitor. Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds
• Positive Sentiment: Regulatory pressure on a competitor: Eli Lilly received an FDA request for more safety data on its oral weight‑loss pill, which could slow competitor momentum and indirectly benefit Novo’s market share. Lilly Stock Dips on FDA Request for More Foundayo Safety Data. Is the Market Reaction Overblown?
• Neutral Sentiment: Novo is advancing etavopivat into late‑stage trials for thalassemia, signaling diversification beyond obesity/diabetes but with longer time and development risk before meaningful commercial impact. Novo Nordisk’s Etavopivat Trials Put Rare Blood Disorders In Focus
• Neutral Sentiment: Company reportedly added ~2,000 staff this year — supports scaling commercial and R&D capacity for launches but may increase near‑term operating costs. Novo Nordisk has reportedly added 2,000 to workforce this year
• Neutral Sentiment: Analyst commentary (Zacks blog) highlights Novo among healthcare names — useful for sentiment but not a direct catalyst. The Zacks Analyst Blog Highlights Netflix, PepsiCo, Novo Nordisk, Hawthorn Bancshares and Park Aerospace
• Negative Sentiment: Rising generic competition: India’s Hetero targets annual sales of 1.5M semaglutide pens in global rollout — a potential long‑term headwind to pricing and market share in lower‑cost segments. Indian's Hetero targets annual sales of 1.5 million semaglutide pens in global rollout

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Balboa Wealth Partners increased its holdings in shares of Novo Nordisk A/S by 12.0% in the 1st quarter. Balboa Wealth Partners now owns 13,333 shares of the company's stock valued at $490,000 after acquiring an additional 1,432 shares during the last quarter. Monarch Capital Management Inc. grew its stake in Novo Nordisk A/S by 44.2% during the 1st quarter. Monarch Capital Management Inc. now owns 14,285 shares of the company's stock worth $536,000 after buying an additional 4,381 shares during the last quarter. Rockefeller Capital Management L.P. grew its stake in Novo Nordisk A/S by 77.2% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,340,858 shares of the company's stock worth $68,223,000 after buying an additional 584,275 shares during the last quarter. Larry Mathis Financial Planning LLC purchased a new position in Novo Nordisk A/S during the 4th quarter worth approximately $535,000. Finally, PeakShares LLC purchased a new position in Novo Nordisk A/S during the 4th quarter worth approximately $491,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 0.2%

Shares of NVO traded up $0.07 during mid-day trading on Thursday, reaching $40.88. The company's stock had a trading volume of 16,046,105 shares, compared to its average volume of 15,982,709. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44. The stock has a market cap of $182.53 billion, a PE ratio of 11.78, a price-to-earnings-growth ratio of 9.62 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The company's 50 day moving average is $40.22 and its 200 day moving average is $48.57.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th were issued a $1.2751 dividend. The ex-dividend date was Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S's dividend payout ratio is presently 50.43%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on NVO shares. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, February 23rd. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Jefferies Financial Group raised Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a research report on Thursday, February 12th. TD Cowen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price target on the stock. in a research report on Tuesday, March 10th. Finally, Morgan Stanley raised Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target on the stock in a research report on Tuesday, March 3rd. Four equities research analysts have rated the stock with a Buy rating and twenty have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.